Introduction {#s1}
============

Dopamine and its receptors play fundamental roles in controlling neurological processes including motor control, cognition, learning, and emotions ([@bib4]). Dopaminergic dysfunction is associated with the pathophysiology of various disorders such as schizophrenia, mood disorders, attention-deficit disorder, Tourette\'s syndrome, substance dependency, and Parkinson\'s disease ([@bib23]). The dopamine receptor family, which belongs to the G-protein-coupled receptor (GPCR) superfamily, can be divided into two subfamilies, namely the D1-like subfamily (including dopamine receptor D1 (DRD1) and DRD5), and the D2-like subfamily (including DRD2, DRD3, and DRD4). These subfamilies probably originated from two independent acquirements of the ability of dopamine binding during the evolution of biogenic amine receptors ([@bib42]). The D1- and D2-like subfamilies are coupled to different G proteins, activating distinct downstream signaling pathways ([@bib39]). In particular, DRD1 and DRD5 are found exclusively in postsynaptic sites of dopamine-receptive neurons. After binding dopamine, they activate Gα~s/olf~ proteins and upregulate the adenylyl cyclase activity in the cell. In comparison, DRD2, DRD3, and DRD4 are expressed both presynaptically on dopaminergic neurons and postsynaptically on dopamine target cells. They activate Gα~i/o~ proteins and thus downregulate the adenylyl cyclase activity ([@bib56]; [@bib46]).

Recent advances in GPCR structure biology make it possible to solve the mystery of dopamine receptors and their signaling pathways. To date, the structures of all three types of D2-like receptors have been reported: In 2010, the crystal structure of human DRD3 was solved ([@bib13]), followed by crystal structures of human DRD4 ([@bib63]) and DRD2 ([@bib64]). In agreement with their high degree of sequence homology, ligand-binding pockets in these D2-like receptors share many structural features in addition to their conserved overall folding. These structural studies expand our understanding of the distinctive selectivity spectrum of the binding pockets of dopamine receptors toward different ligands including those belonging to the same chemical category but containing subtle modifications.

DRD4 is characterized by its more selective expression pattern in the brain (such as the frontal cortex and amygdala; [@bib38]), and thus exhibits promising pharmacological properties. Their anatomical localization in the prefrontal cortex, in contrast to little or no expression in the basal ganglia, strongly indicates roles of DRD4 receptors in cognition and emotions. Although dopamine is the most potent endogenous ligand known to activate DRD4, the receptor is also readily activated by epinephrine and norepinephrine ([@bib40]). In addition, clozapine binds to DRD4 with an affinity 10-fold higher than that to other dopaminergic receptors ([@bib6]; [@bib65]). To date, the highest degree of selectivity for dopaminergic receptors having been achieved by pharmaceutics are certain DRD4-selective antagonists, exhibiting more than 1000-fold higher affinity towards D4 receptors compared to other dopaminergic receptors ([@bib46]). One well-characterized selective DRD4-antagonist with high affinity (K~i~ \~0.43 nM) is a 1,4-disubstituted aromatic piperidine/piperazine (1,4-DAP) compound named L745870 ([@bib43]). L745870 has been extensively analyzed for its pharmacology in various behavioral tests (in rodents) and clinical trials for treating schizophrenia ([@bib43]; [@bib8]).

To facilitate future pharmacological studies and possible improvement of related compounds, we determined the 3.5 Å resolution crystal structure of mouse DRD4 (66% identical to the human DRD4 in the whole amino acid sequence and 89% identical in the transmembrane (TM) region) in complex with L745870. This complex structure shows the existence of an extended ligand-binding pocket specific for DRD4s and improved our understanding of the structural bases of subfamily-selectivity of potential antagonists.

Results {#s2}
=======

Overall structures {#s2-1}
------------------

To crystallize the mouse DRD4 (simply referred to as DRD4 hereafter unless otherwise specified), we used protein engineering ([@bib16]; [@bib10]) in combination with lipidic cubic phase (LCP) methods ([@bib9]). Recombinant proteins were purified and crystallized in the presence of the subtype-selective antagonist, L745870, to stabilize the receptor ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). To aid crystallization, we replaced the long, presumably disordered, intracellular loop 3 (ICL3, that is residues A220^5.70^--A302^6.24^) of the receptor with a thermo-stable variant of apocytochrome b~562~ (BRIL) ([@bib16]). To improve the diffraction quality of the DRD4 crystal, we truncated the N-terminal 22 amino acid residues, which fail to adopt an ordered secondary structure according to bioinformatic predictions. This N-terminal peptide was replaced by a FLAG-tag without interfering with the overall structure. To the contrary, the tag appeared to facilitate the crystallization process. The crystallized recombinant DRD4 protein contained four additional point mutations, F121^3.41^W, P201^5.52^I, P317^6.38^A, and C181^45.51^R (superscript numerals refer to the Ballesteros-Weinstein numbering system; [@bib3]). The first mutation is based on a previously reported stabilizing mutation in class-A GPCRs ([@bib47]) ([Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"}). The remaining three mutations were designed based on sequence comparison of the D2-like subfamily ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}) and were predicted not to impair the native binding ability of the receptor. In particular, P201^5.52^I and P317^6.38^A were found to be necessary for proper crystallization, while C181^45.51^R improved the diffraction quality. The combination of these modifications (including the BRIL fusion) increased the melting temperature (Tm) of the protein variant by 13°C compared to the wild-type protein (WT, without the ICL3 substitution), and the presence of L745870 further increased the Tm by 20°C ([Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"}). The DRD4 crystal structure was refined at 3.5 Å resolution ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). Furthermore, a recently reported technique utilizes a cpGFP (circular permuted GFP)-fusion dopamine receptor variant as an in vivo dopamine-binding reporter ([@bib44]; [@bib58]). Based on this method, we confirmed that the mutation variant used for structural determination (with BRIL replaced by cpGFP) maintained significant ability to response to both agonists and antagonists ([Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}).

The overall structure of the TM domain of mouse DRD4 was similar to the previously reported ground-state structures of human DRD4 and DRD3 ([@bib13]; [@bib63]). Our DRD4 crystal possessed a typical type-I crystal packing of membrane proteins, with the TM regions forming continuous layers. Moreover, DRD4 formed a non-symmetrical dimer in each crystallography asymmetric unit. The two protomers are denoted as Mol-A and Mol-B, and are related to each other by a 44° rotation about an axis perpendicular to the membrane plane in addition to a non-crystallographic translation ([Figure 1a,b](#fig1){ref-type="fig"}). TMs 5 and 6 of the receptor form continuous helices with a helix pair from the helix bundle of the BRIL fusion. This intact helix structure seems to provide more rigid packing which may explain why the P201^5.52^I and P307^6.38^A mutations facilitated crystallization. Structures of the FLAG-tag and N-terminal residues 23--30 failed to be resolved, presumably due to their flexibility or multiple conformations. Well-defined electron densities were observed for ICL1, extracellular loop-1 (ECL1), and ECL3. In contrast, electron density of ECL2 in Mol-B broke near the signature C105^3.25^-C180^45.50^ disulfide bond, and residues between the C-terminal end of TM4 and the conserved C180^45.50^ were unsolvable from the density. In comparison, the ECL2 of Mol-A showed a clear electron density at the C-terminal end of TM4, but became disordered near the N-terminal end of TM5. This stability difference between the two ECL2 loops is likely to be due to distinct crystal packing interactions ([Figure 1---figure supplements 3](#fig1s3){ref-type="fig"} and [4](#fig1s4){ref-type="fig"}). Based on the quality of the electron density map as well as the distribution of B-factors ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}), the most stable regions of the entire dimer were the dimer interface and BRIL helices fused with TMs 5 and 6 in Mol-B. Thus, the dimer appeared to serve as a structural unit of crystal packing. In comparison, the BRIL molecule fused with Mol-A exhibited a higher flexibility. The C-termini of the both protein molecules were also disordered, with only a short segment of helix-8 being resolved in each protomer.

![The overall structure of mouse DRD4 in complex with L745870.\
(**a**) Ribbon representation of mouse DRD4 (TM domain presented in cyan, ligand in yellow, and BRIL fusion in orange), as viewed parallel to the membrane with approximate membrane boundaries indicated with gray lines. (**b**) Top view of the mouse DRD4 structure. Rotation angle between Mol-A and Mol-B calculated with PyMOL is shown as a red angle sign. (**c**) The L745870 antagonist is shown in stick representation with carbon, nitrogen and chloride atoms shown in yellow, blue, and green, respectively. Fo−Fc omit density map for L745870 is contoured at 2.5 σ. (Also see [Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}) (**d**) Chemical structure of L745870.](elife-48822-fig1){#fig1}

Ligand-binding pocket {#s2-2}
---------------------

Clear electron density was observed in the ligand-binding pocket in Mol-B; in comparison, the electron-density omit map was murky at the corresponding position in Mol-A ([Figure 1c](#fig1){ref-type="fig"}). Nevertheless, including L745870 in Mol-A in a conformation similar to that in Mol-B during refinement successfully reduced the R-factors, albeit only slightly. Because of the limited resolution of our crystal structure, we do not further speculate the biological significance of the differential binding of L745870 in the non-symmetrical dimer ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Here, we describe the binding pocket of DRD4 on the basis of L745870 bound to Mol-B. This antagonist was buried in the upper part of the TM core underneath the signature C105^3.25^-C180^45.50^ disulfide bond ([Figure 2a,b](#fig2){ref-type="fig"}). The binding pocket was formed by residues from TMs 2, 3, 5, 6, and 7. Furthermore, L745870 is a typical 1,4-DAP compound ([Figure 1d](#fig1){ref-type="fig"}), which presents a common characteristic of many high-selectivity ligands of D4 receptors ([@bib41]). A proton-titratable amine group exists in the core piperazine on the arm side of the heterocyclic ring ([@bib31]), and formed a hydrogen bond (2.9 Å) with the acidic residue, D112^3.32^, conserved in all members of the aminergic receptor family. Simultaneously, the carboxyl sidechain of D112^3.32^ formed a hydrogen bond with the hydroxyl group of Y358^7.43^, and this hydrogen bond is also conserved in almost all aminergic receptor structures ([@bib63]; [@bib62]; [@bib33]; [@bib17]; [@bib59]). D112^3.32^ serves as the counter ion for the protonated amine group in neurotransmitters such as dopamine, serotonin, and epinephrine ([@bib61]).

![Molecular details of the L745870-binding site in DRD4.\
(**a**) Mesh (Mol-A) and surface (Mol-B) representation of mouse DRD4 as viewed parallel to the membrane plane, clipped to reveal L745870 (colored as in [Figure 1](#fig1){ref-type="fig"}). (**b**) Interactions between the residues confining the binding pocket and L745870 (shown in magenta), with potential polar interactions depicted as dashed red lines. (**c, d**) Top view of surface representation of binding pocket in DRD2/3 and DRD4, respectively. L745870 is colored as in [Figure 1](#fig1){ref-type="fig"}. (**e**) Structural differences in the extended binding pockets (EBPs) of DRD4 (cyan), DRD2 (gray), and DRD3 (magenta). L745870 is shown as a space-filling model with carbon, nitrogen, and chloride atoms shown in cyan, blue, and green, respectively. (**f**) Comparison of nemonapride and L745870 in 3D models as well as 2D structures. The protonatable amino groups are marked with dashed lines in the 2D structures. For nemonapride, protonation occurs both at positions 1 and 2, whereas for L745870 it occurs mainly at position 1. The 3D steric conformations were generated with Maestro using the ligand preparation mode.](elife-48822-fig2){#fig2}

Orthosteric pocket {#s2-3}
------------------

The heterocyclic ring of L745870 resides in the relatively hydrophobic orthosteric pocket, surrounded by V113^3.33^, F330^6.51^, and F331^6.52^ from both sides, and by C116^3.36^ and W327^6.48^ from the bottom. In our cpGFP-based dopamine-activation assay, the F330^6.51^Y mutation, which left the aromatic moiety unchanged, showed no detectable defect on the binding of dopamine or other ligands used ([Figure 2---figure supplement 1b](#fig2s1){ref-type="fig"}).

The well-conserved residues S191^5.42^ and S192^5.43^, which are postulated to function as hydrogen-bond acceptors for the hydroxyl groups of bioamines during dopamine activation ([@bib57]; [@bib18]), were found to be positioned away from L745870 in our complex structure, probably because of the lack of hydroxyl groups in the pyridine part of the ligand. Moreover, our cpGFP-based dopamine-activation assay ([Figure 2---figure supplement 1b](#fig2s1){ref-type="fig"}) showed that, to induce the fluorescence intensity change (*i.e.*, to activate the receptor), the S191^5.42^A -containing variants required 100-fold higher concentrations of dopamine compare to the WT construct. In comparison, the S192^5.43^A mutation slightly interfered with the dopamine-induced conformational change. In addition, the S195^5.46^A mutation completely abolished the activating ability of dopamine. In agreement with previous reports (reviewed in [@bib35]), our functional studies suggest that the three adjacent serine residues within the orthosteric pocket play crucial roles in receptor activation by dopamine.

Extended pocket {#s2-4}
---------------

The chlorophenyl arm of L745870 was observed to protrude into an extended pocket of our mouse DRD4 structure, which is also present in the human DRD4 structure ([@bib63]). In particular, the ligand-binding pocket of DRD4 extended from the orthosteric pocket into a crevice between TM2 and TM3, rather than a crevice between TM2 and TM7 as observed in the D2 and D3 receptors ([Figure 2c,d](#fig2){ref-type="fig"}). This extended pocket was surrounded by residues L83^2.56^, F88^2.61^, S91^2.64^, L108^3.28^, and M109^3.29^, with the signature C105^3.25^-C180^45.50^ disulfide bond and W98^23.50^ (a conserved residue in the connecting loop between TMs 2 and 3) located on the top of the pocket. However, a few structural features around TM2 appear to limit further extension of the pocket. For instance, while providing hydrophobic interactions with the piperazine group of L745870, F88^2.61^ obstructed further extension. Similarly, a hydrogen bond between E92^2.65^ and S351^7.36^ appeared to function as a lock restricting the extension ([Figure 2b](#fig2){ref-type="fig"}). In agreement with these structural observations, our cpGFP-based dopamine-activation assays showed that small-to-large mutations S91^2.64^L and L108^3.28^F dramatically reduced the inhibitory effects of L745870 against dopamine activation. Even more drastically, the S91^2.64^F mutation abolished the response of the receptor to dopamine ([Figure 2---figure supplement 1c](#fig2s1){ref-type="fig"}).

Dimerization {#s2-5}
------------

Our crystal structure of DRD4 revealed a non-symmetrical interface between TMs 1--3 of Mol-A and TMs 5 and 6 of Mol-B. Following dimerization, a total of 1600 Å^2^ 'solvent-accessible surface' was buried within the dimer. To our knowledge, such a non-symmetrical homodimer has not been described in crystal structures of GPCRs before. The dimerization was stabilized by hydrogen bonds from both extracellular and intracellular regions, as well as hydrophobic packing between the transmembrane domains ([Figure 3a](#fig3){ref-type="fig"}). In particular, a polar interaction between S101^A3.21^ and D186^B5.37^ (the superscript letter, A or B, denotes the host protomer of the corresponding residue) linked the extracellular sides of TM3^A^ and TM5^B^, whereas a hydrophobic interaction on the same side of TM2^A^ and TM6^B^ was formed through Y90^A2.63^ and L339^B6.60^, together with a disulfide bridge within ECL3 of Mol-B ([Figure 3b](#fig3){ref-type="fig"}). On the intracellular side, two hydrogen bonds (namely between the mainchain of A57^A1.58^ and the sidechain of T135^B3.55^, and between the sidechain of S58^A1.59^ and the mainchain of G213^B5.64^) and a salt-bridge bond between E59^A1.60^ and R216^B5.67^ stabilized the packing of TM1^A^, TM3^B^, and TM5^B^ ([Figure 3c](#fig3){ref-type="fig"}). These interacting regions formed a stabilizing triangle, locking the dimer interface of aliphatic interactions of the TM region in a stable conformation. Results from our cross-linking experiment further suggest that dimerization of recombinant DRD4 molecules also occurs in solution ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

![Interface details of mouse DRD4 in the asymmetric dimer.\
(**a**) Overview of the interface of the mouse DRD4 dimer. Dot representations of the interacting residues are shown for the transmembrane domain (gray) and exo-membrane regions (colored). (b, c) Extracellular and intracellular faces of the DRD4 dimer. Red dashed lines depict potential polar interactions.](elife-48822-fig3){#fig3}

Discussion {#s3}
==========

In this study, we present the structure analysis on DRD4 complexed with its antagonist L745870. Comparison of our complex structure with known structures of DRD2, DRD3, and DRD4 reveals the structural basis of subtype-selectivity ([Figure 2e](#fig2){ref-type="fig"}). As suggested by previous reports ([@bib55]; [@bib49]), the subtype-specific determinants that contribute to the ligand selectivity within the D2-like subfamily are located near the extracellular ends of TMs 2 and 3. Receptors of this subfamily share the same set of residues in the orthosteric binding pocket to maintain dopamine binding ability. More importantly, less conserved residues in TMs 2 and 3 contribute micro-patches to the pocket that discriminates different substitutions of the ligands. For instance, in DRD2/3-antagonist complex structures, a smaller aliphatic sidechain at V^2.61^ (compared to F88^2.61^ in DRD4) allows ligands specific to the DRD2/3 subfamily to be oriented toward a crevice between TMs 1--2 and TM7 ([@bib13]). In addition, previous experiments substituting amino acid residues at less conserved positions in the D4 receptor with corresponding residues from DRD2 or constructing D2/D4 and D4/D2 hybrids with the chimeric junction located near the N-terminal portion of TM3 showed to switch the pharmacological profiles of the variants. In particular, DRD4-selective ligands showed decreased binding affinity to DRD4 variants constructed in such a manner ([@bib31]; [@bib53]). Importantly, steric clashes will occur at positions of S^2.64^L and L^3.28^F in DRD2/3 or W^23.50^ in DRD2, if L745870 is superimposed into their corresponding ligand-binding pockets ([Figure 2](#fig2){ref-type="fig"}).

From a pharmaceutical point of view, pluridimensional efficacy and adverse effects of a given drug result from its nonspecific interactions with unintended targets. Therefore, increasing the receptor-discriminating ability of lead compounds has long been a major focus of drug design and pharmaceutics. Ligands bound in the previously reported crystal structures of the D2, D3, and D4 receptors are risperidone, eticlopride, and nemonapride, respectively, all of which represent non-selective ligands. In particular, risperidone is known to bind to all D2-like receptors as well as other types of aminergic receptors ([@bib28]); eticlopride is a DRD2/D3-selective antagonist ([@bib29]); and nemonapride is both an antagonist of D2-like receptors and a potent agonist of the serotonin 1A (5-HT1A) receptor ([@bib51]). Our crystal structure of the DRD4-L745870 complex provides a critical model to decipher the subtype selectivity of ligands, a characteristic of the D2-like receptors. Most classic biogenic amine ligands of aminergic receptors (agonists or antagonists, including L745870) possess a protonated amine group that binds the conserved D^3.32^ site ([@bib59]; [@bib54]; [@bib45]; [@bib37]). This specific interaction partially explains why L745870 and dopamine compete for binding the DRD4. Furthermore, by reducing the moving freedom of TM3 required for full activation of class-A GPCRs ([@bib27]), the bulky chemical group of L745870 inserted into the TM2-TM3 crevice may provide a structure basis for its antagonist activity. Being consistent with this notion, the results of our mutational analysis showed that, when substituting S^2.64^ in the TM2-TM3 cavity with a bulky sidechain (such as Leu or Phe), the dopamine-induced activity was decreased or totally abolished ([Figure 2](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). To further elaborate the discrepancy between the chemical structures of L745870 and nemonapride and its relationship to the binding modes inside DRD4, we performed a molecular docking analysis using the program Schrodinger ([@bib22]). Under the same set of simulation conditions, a nemonapride molecule assumes up to 11 steric conformations with each containing two protonated sites; in contrast, two conformations are observed for L745870, and only one of them is able to form a hydrogen bond to D^3.32^([Figure 2f](#fig2){ref-type="fig"}). Upon anchoring the central proton-titratable amino group of the ligand to D^3.32^, the more hydrophilic entity on one side occupies the dopamine-binding orthosteric pocket, while the more hydrophobic entity on the other side protrudes into the extended pocket. Torsion angles between the three parts appear to play important roles in determining the ligand-binding mode. These observations clearly explain why nemonapride can bind to both D4 and D2/3 receptors whereas L745870 possesses high selectivity toward the D4 receptor, thus suggesting a direction to improve the ligand potency for the D2-like subfamily.

GPCR oligomerization has been proposed to modulate trafficking, cooperativity of ligand-binding, and signaling efficacy ([@bib21]). Accumulating experimental evidence suggests that certain class-A GPCRs form homo- and hetero-oligomers, in both transfected cells as well as extracted tissues. Symmetrical, parallel, dimeric interfaces have been observed in multiple crystal structures of class-A GPCRs, supporting the biological relevance of GPCR dimerization ([@bib25]; [@bib34]; [@bib26]; [@bib66]; [@bib32]). However, non-symmetric dimerization is rarely seen in crystal structures of class-A GPCRs. A case similar to what we observed in DRD4 crystal is revealed in a previously reported complex structure of the α~2A~ receptor crystallized with a high-affinity antagonist ([@bib32]). Nevertheless, in the α~2A~ receptor case lipids and cholesterols were trapped in the interface groove, preventing any direct contact between the protomers. Moreover, our structural observations are in agreement with results from single-molecule dynamic studies showing that dimerization and/or oligomerization of GPCRs are more dynamic than previously believed ([@bib48]). More intriguingly, it had been reported that, when co-expressed, two different epitope-tagged D4 receptors can be co-immuno-precipitated, suggesting that multiple DRD4 molecules form dimeric/oligomeric complexes within the cell membrane ([@bib41]). The observed unusual non-symmetric dimerization in our crystal structure may suggest a mechanism of concentration-dependent regulation of the DRD4 activity in membrane, which deserves more rigorous in vivo verification in the future.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                     Designation                                Source or\                 Identifiers                   Additional\
  (species) or resource                                                                        reference                                                information
  ------------------------------------------------- ------------------------------------------ -------------------------- ----------------------------- -----------------------------------------------
  Gene (*Mouse*)                                    DRD4                                       SUNGENE BIOTECH            GenBank: BC051421.1           

  Cell line (*Spodoptera frugiperda*)               Sf9 and High5                              Thermo Fisher Scientific   Sf9: B825-01\                 
                                                                                                                          High5:B85502                  

  Cell line (*Homo sapiens*)                        HEK293t                                    ATCC                       catalog numbers: CRL-3216     

  Transfected construct (*Spodoptera frugiperda*)   pFastBac1-DRD4-BRIL                        This paper                                               Crystal construct

  Transfected construct (*Homo sapiens*)            pcDNA3.1-DRD4-cpGFP                        This paper                                               Fluorescent sensor-based ligand-binding assay

  Recombinant DNA reagent                           pFastBac1                                  Thermo Fisher Scientific   catalog numbers: 10359016     

  Recombinant DNA reagent                           pcDNA3.1\                                  Thermo Fisher Scientific   catalog numbers: V79020       Mammalian expression vector
                                                    (plasmid)                                                                                           

  Commercial assay or kit                           Bac-to-Bac Baculovirus Expression system   Thermo Fisher Scientific   Catalog number: 10359016      

  Chemical compound, drug                           L745870                                    Tocris                     Catalog number: 158985-00-3   

  Software, algorithm                               XDS program package                        [@bib30]                                                 

  Software, algorithm                               PHENIX                                     [@bib1]                                                  

  Software, algorithm                               Maestro                                    SCHRÖDINGER                                              

  Software, algorithm                               Fiji                                       [@bib50]                                                 
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Expression and purification of DRD4-BRIL {#s4-1}
----------------------------------------

We generated a mouse DRD4 construct containing the A1--L106 region of the BRIL (with the point mutations M7W, H102I, and R106L) from *Escherichia coli* in the place of residues A220^5.70^--A302^6.24^ of the receptor ICL3 ([@bib16]). This chimera construct of DRD4 was subcloned into a modified pFastBac1 vector (Thermo Fisher) that contained an expression cassette with a hemagglutinin (HA) signal sequence followed by a FLAG-tag at the N-terminus of the receptor sequence and a PreScission Protease (PPase) recognition site followed by EGFP (enhanced GFP) and a His~10~-tag at the C-terminus. The fusion protein was expressed using the Bac-to-Bac Baculovirus Expression System (Thermo Fisher) in High 5 strain of *Spodoptera frugiperda* cells for 48 hr. Harvested cells were then flash-frozen in liquid nitrogen and stored in --80°C until further use.

Cell membranes were obtained by Dounce homogenization using purification buffer A \[25 mM HEPES (pH 7.4) and 150 mM NaCl\]. Washed membranes were resuspended in buffer B \[25 mM HEPES (pH 7.4), 150 mM NaCl, 30 µM L745870 (Tocris, Cat.\# 158985-00-3), and 0.2% (w/v) iodoacetamide\], with 80 mL buffer B per 0.4 L cultured biomass, and incubated at 4°C for 1 hr. The membrane was then solubilized by adding a detergent mixture \[final 1% (w/v) n-dodecyl-β-D-maltopyranoside (DDM; Anatrace), and 0.15% (w/v) cholesteryl hemisuccinate (CHS; Sigma Aldrich)\] for 1.5 hr at 4°C. The supernatant was isolated by centrifugation at 150,000 × *g* for 30 min. TALON IMAC resin (2 mL; Clontech) in 5 mM imidazole (pH 7.5) was added to the supernatant. The mixture was incubated at 4°C for 2--3 hr. The resin was transferred into a gravity column and washed with 15 column volumes of wash buffer C \[25 mM HEPES (pH 7.4), 150 mM NaCl, 0.05% (w/v) DDM, 0.015% (w/v) CHS, 30 mM imidazole, and 30 µM L745870\]. The resin-binding protein was then treated overnight with homemade His-tagged PPase in 10 mL buffer C. The flow through was then concentrated to 1 mL before being loaded onto a Superdex-200 column (GE healthcare). Fractions were collected from the monodispersed peak ([Figure 1---figure supplement 1b](#fig1s1){ref-type="fig"}) and pooled into one tube. L745870 (final concentration 50 µM) was added to the pooled protein sample and equilibrated for 1 hr before being concentrated to \~60 mg/mL with a 50 kDa cut-off centrifuge concentrator (Millipore).

Lipidic cubic phase crystallization {#s4-2}
-----------------------------------

The protein sample was reconstituted into LCP by mixing 40% sample with 60% lipid \[10% (w/w) cholesterol, and 90% (w/w) monoolein\] using the twin-syringe method ([@bib9]). The protein-lipid mixture was dispensed as 40 nL drops onto glass sandwich plates (Shanghai FAstal BioTechô Inc) using a hand-held dispenser (Art Robbins Instruments) and overlaid with 0.8 µL of precipitant solution. Protein crystals were obtained from precipitant solution containing 100 mM citrate acid/NaOH (pH 5.0--6.0), 0--150 mM salts, and 30% PEG550DME or PEG600 ([Figure 1](#fig1){ref-type="fig"}-figure Supplements 1c~i-iv~). The best crystals grew in 100 mM MES (pH 6.0), 50 mM ammonium citrate, and 30% PEG400 ([Figure 1---figure supplement 1cv](#fig1s1){ref-type="fig"}). Crystals grew to a full size of \~50 µm×20 µm×5 µm within one week, and were harvested directly from the LCP matrix using 50 µm micromounts (MiTeGen, Cat.\# M2-L19-50), before flash-frozen in liquid nitrogen until further use.

Data collection, structure solution and refinement {#s4-3}
--------------------------------------------------

X-ray diffraction data were collected at the SPring-8 beamline 41XU, Hyogo, Japan, using an EIGER16M detector (Dectris; X-ray wavelength 1.0000 Å). A raster system was used to locate the best diffracting parts of single crystals ([@bib12]). The crystals were exposed to a 10 μm unattenuated mini-beam for 0.1 s and 0.2° oscillation per frame. Most crystals of the DRD4-L745870 complex diffracted to a resolution of 3.5--4.0 Å. The software package, XDS ([@bib30]), was used for integrating and scaling data from 28 best-diffracting crystals.

The DRD4-L74570 complex was solved by molecular replacement using the PHENIX program ([@bib1]; [@bib20]) and two independent search models, namely, the receptor portion of human DRD4 (PDB ID: 5WIU) ([@bib63]) and the BRIL protein (PDB ID: 1M6T) ([@bib15]). Refinement was performed with PHENIX_REFINE, iterated with visual examination and rebuilding of the refined model using the program COOT ([@bib20]) and \|2F~o~\|--\|F~c~\|, \|F~o~\|--\|F~c~\|, and omit maps. Simulation of ligand docking in receptor was done with Maestro (SCHRÖDINGER)([@bib22]).

Fluorescent sensor-based ligand-binding assay {#s4-4}
---------------------------------------------

Sequences encoding a cleavable HA secretion-signaling motif and a FLAG epitope were placed at the 5'-end of the DRD4 constructs (WT\* and 'Crystal' in [Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}). *Sal*I and *Not*I cleavage sites were created at the 5'- and 3'-ends, respectively, for cloning into pcDNA-3.1 (Thermo Fisher) to generate all mammalian cell-expression constructs.

Coupling between conformational changes and chromophore fluorescence were anticipated to follow the reported example of dLight1 ([@bib44]) which is a DRD2 variant. In particular, the cpGFP module (LSSLE-cpGFP-LPDQL) was copied from the plasmid GCaMP6 ([@bib11]) and inserted into DRD4 variants of WT\* and point mutations as well as the 'crystallization' construct to replace the segment of R217^5.67^--W306^6.28^.

Cell culture, imaging, and quantification {#s4-5}
-----------------------------------------

HEK293T cells were cultured in glass-bottom cell-culture dish (NEST, Cat.\# 801001) and transfected with DRD4-cpGFP expression plasmid using polyetherimide (Sigma Aldrich). Cell imaging was performed using a 60 × oil based objective on an inverted OLYMPUS FV1200 laser scanning confocal microscope with 488/513 nm ex/em wavelengths. For testing DRD4-cpGFP responses, different ligands were directly applied to the bath during the imaging session. Reproducible results were obtained after repeating all assays 2--3 times. Mean intensity of ROI (region of interested) in every frame was calculated using the Fiji software ([@bib50]). No commonly misidentified cell lines were used. The cell lines are negative for mycoplasma contamination.

Protein cross-linking {#s4-6}
---------------------

Purified protein (1 mg/mL) was incubated with serial dilutions (0--5 mM) of glutaraldehyde dissolved in reaction buffer \[25 mM HEPES (pH 7.4), 150 mM NaCl, 0.05% (w/v) DDM, and 0.015% (w/v) CHS\] at room temperature for 1 hr. Cross-linking was stopped by adding in 5 × loading buffer \[250 mM Tris-HCl (pH 6.8), 10% (w/v) SDS, 0.5% (w/v) bromophenol blue, 50% (v/v) glycerol, and 5% (w/v) β-Mercaptoethanol\] before the sample was analyzed by SDS-PAGE.
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###### Data collection and refinement statistics for the mouse DRD4 and L745870 complex.

^a^. Values in parentheses present the highest resolution shell. CC~1/2~\*\* ([@bib19]). ^b^. All outliers are located in loops not involved in ligand binding.
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Diffraction data have been deposited in PDB under the accession code 6IQL.

The following dataset was generated:
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

This manuscript described the crystal structure of mouse dopamine D4 in complex with a selective antagonist L745870. The structure, together with earlier human D4 structure, revealed an extended binding pocket in addition to the orthosteric pocket. The structure also explained the subtype selectivity of L745870 as this ligand inserted into the extended binding pocket formed by helices II and III in D4, in contrast to a different extended pocket in D2/D3. Using the cpGFP-fusion assay combined with mutagenesis study, the author proposed a reasonable antagonism mechanism of L745870. A unique feature is that they found the structure is a non-symmetric dimer in crystal and tried to verify it in solution. While there are still debates about the dimeric conformation and necessity of GPCR, but it is surely meaningful to see and discuss this non-symmetric conformation. In summary, this paper reveals the ligand selectivity among different dopamine receptors and also shows how L745870 series ligands can inhibit receptor activity.

**Decision letter after peer review:**

Thank you for submitting your article \"Crystal structure of dopamine receptor D4 bound to the subtype-selective ligand, L745870: selectivity and antagonism\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Olga Boudker as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Zhi-Jie Liu (Reviewer \#1).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Essential revisions:

1\) The cross-linking study should be conducted while proteins are on the cell membrane as this will mimic and trap the physiological non-symmetry dimer; in contrast, proteins in detergent micelle may be linked by glutaraldehyde artificially. Alternatively, the author may add a monomeric GPCR as negative control with the current method. What are the cross-linkable residues on the identified dimer interface that may be responsible for Figure 3---figure supplement 1?

2\) Is there a pharmacological study comparing the efficiency of ligand L745870 against mouse and human D4 receptor? Can we get some clue based on the current crystal structure and sequence alignment between human and mouse? Since the human D4 structure is also available is it possible to discuss how ligand potency for either L745870 or other ligands can be improved?

3\) Based on Figure 1---figure supplement 1, L745870 appears to have lost significant potency on the engineered constructs. The results in that figure are difficult to interpret, as \"L-7\" was always in micromolar range. Some routine molecular pharmacology, such as radioligand binding or functional assays would help to convincingly confirm that the crystallization construct retains high affinity for L745870.

4\) The structure is of relatively low resolution (3.5 Å), how did the authors determine and confirm the orientation of L745870, which has a linear shape, in the binding site? Some simple molecular dynamics simulations showing the stability of the binding pose would strengthen the argument, especially given that Figure 1C shows L745870 may have different binding poses in Mol-A and Mol-B.

5\) While the analysis recapitulates previously identified TM2 and TM3 micro-patch on receptor side, it is not clear why L745870 has much higher affinity for DRD4 than for DRD3 and DRD2 on the ligand side, or why L745870 is selective but nemonapride is not, as nemonapride protrudes into the EBP shown in Figure 2E as well. Either more discussion or more analysis is warranted to further elaborate this point.

10.7554/eLife.48822.sa2

Author response

> Essential revisions:
>
> 1\) The cross-linking study should be conducted while proteins are on the cell membrane as this will mimic and trap the physiological non-symmetry dimer; in contrast, proteins in detergent micelle may be linked by glutaraldehyde artificially. Alternatively, the author may add a monomeric GPCR as negative control with the current method. What are the cross-linkable residues on the identified dimer interface that may be responsible for Figure 3---figure supplement 1?

We thank the reviewers' suggestion. It would be more solid if we could confirm the dimer state in the in vivo environment. In fact, we did try to perform the crosslinking experiment in the cell membrane. However, the results were less clean than just in the presence of detergent; higher order aggregation and oligomerization existed after trying different concentrations of crosslinking agents. Based on our crystal structure, the most probable crosslinking sites in the detergent environment include Arg376 on Helix 8 of protomer A, and Arg216, Arg215 on the cytosol side of TM5 from protomer B.

> 2\) Is there a pharmacological study comparing the efficiency of ligand L745870 against mouse and human D4 receptor? Can we get some clue based on the current crystal structure and sequence alignment between human and mouse? Since the human D4 structure is also available is it possible to discuss how ligand potency for either L745870 or other ligands can be improved?

A previous study (Patel et al., 1997) showed that there was no significant species difference in terms of affinity of L-745,870 towards the human and rodent D4 receptors, which is consistent with the sequence conservation and structure alignment. Meanwhile, most of the pharmaceutical evaluation of L-745,870 was performed in rodents. As one of the ligands of highest selective affinity towards D4 receptors and behaving well in pharmacokinetic trials, L-745870 remains to be a potential drug for clinic use though it failed in treating schizophrenia. New clinic trials are conducted for other disease recently. The drug design question is addressed together with "Question 5".

> 3\) Based on Figure 1---figure supplement 1, L745870 appears to have lost significant potency on the engineered constructs. The results in that figure are difficult to interpret, as \"L-7\" was always in micromolar range. Some routine molecular pharmacology, such as radioligand binding or functional assays would help to convincingly confirm that the crystallization construct retains high affinity for L745870.

Compared with radio-ligand binding, the fluorescence assay showed lower signal noise ratio and was used mainly for large scale qualitative analyses. In this assay, fluorescence signals came from dopamine binding towards the engineered GFP-D4 receptor, and the antagonists were added afterwards to the same basin. Due to the limited fluorescing window of the GFP component, the change of signal should be recorded in a short time. Therefore, relatively high concentrations of competitive ligands were used. However, the binding affinity of L745870 towards the engineered receptors likely remains high, since L745870 was able to rapidly replace dopamine in the fluorescence assay, and was required (at a concentration higher than 50 nM) for successful crystallization.

> 4\) The structure is of relatively low resolution (3.5 Å), how did the authors determine and confirm the orientation of L745870, which has a linear shape, in the binding site? Some simple molecular dynamics simulations showing the stability of the binding pose would strengthen the argument, especially given that Figure 1C shows L745870 may have different binding poses in Mol-A and Mol-B.

Thanks the reviewers for this good suggestion. Indeed, L745870 in its free form may assume multiple stereo-chemical conformations, as being confirmed by the programs PHENIX (Liebschner et al., 2019) and Schrodinger (Friesner et al., 2006). However, Asp112 of the receptor is most likely to form a hydrogen bond with proton-titratable amine group in L745870 during the binding, which strongly restricts the freedom of ligand docking. Accordingly, previous analyses (Kortagere et al., 2004; Thal et al., 2016) have proposed a binding mode similar to our refined model. Nevertheless, we are aware that it is possible that the proton-titratable amine group in L745870 occurs in either the 1*H*-pyrrolo\[2,3-*b*\]pyridine side or chlorophenyl side with micro-environment changing. The difference of ligand density between the two protomers appears to be consistent with this possibility.

> 5\) While the analysis recapitulates previously identified TM2 and TM3 micro-patch on receptor side, it is not clear why L745870 has much higher affinity for DRD4 than for DRD3 and DRD2 on the ligand side, or why L745870 is selective but nemonapride is not, as nemonapride protrudes into the EBP shown in Figure 2E as well. Either more discussion or more analysis is warranted to further elaborate this point.

We thank the reviewers for raising this interesting question. Further discussion is added to the related part in Discussion (second paragraph).
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